Шведска - Шведски - Läkemedelsverket (Medical Products Agency)

astron research ltd - metotrexat - injektionsvätska, lösning i förfylld spruta - 50 mg/ml - metotrexat 50 mg aktiv substans

Шведска - Шведски - Läkemedelsverket (Medical Products Agency)

serb s.a. - fomepizolsulfat - koncentrat till infusionsvätska, lösning - 5 mg/ml - fomepizolsulfat 7,99 mg aktiv substans - fomepizol

Европска Унија - Шведски - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - immunsuppressiva - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) är indicerat för behandling av vuxna patienter med tidigare obehandlat multipelt myelom som inte är berättigade till transplantation. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) är indicerat för behandling av vuxna patienter med tidigare obehandlat multipelt myelom som inte är berättigade till transplantation. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Европска Унија - Шведски - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - andra antineoplastiska medel - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Европска Унија - Шведски - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastiska medel - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

Шведска - Шведски - Läkemedelsverket (Medical Products Agency)

mylan ab - buspironhydroklorid - tablett - 10 mg - laktosmonohydrat hjälpämne; buspironhydroklorid 10 mg aktiv substans - buspiron

Шведска - Шведски - Läkemedelsverket (Medical Products Agency)

mylan ab - buspironhydroklorid - tablett - 5 mg - buspironhydroklorid 5 mg aktiv substans; laktosmonohydrat hjälpämne - buspiron

Шведска - Шведски - Läkemedelsverket (Medical Products Agency)

sandoz a/s - gemfibrozil - filmdragerad tablett - 450 mg - gemfibrozil 450 mg aktiv substans; laktosmonohydrat hjälpämne - gemfibrozil

Шведска - Шведски - Läkemedelsverket (Medical Products Agency)

sandoz a/s - gemfibrozil - filmdragerad tablett - 600 mg - laktosmonohydrat hjälpämne; gemfibrozil 600 mg aktiv substans - gemfibrozil

Шведска - Шведски - Läkemedelsverket (Medical Products Agency)

actavis group ptc ehf. - amoxicillintrihydrat; kaliumklavulanat - filmdragerad tablett - 500 mg/125 mg - amoxicillintrihydrat 573,4 mg aktiv substans; kaliumklavulanat 138,9 mg aktiv substans - amoxicillin och enzymhämmare